CADTH

Great-West Life introduces the SMART drug plan   In June 2017, Great-West Life is introducing the SMART drug plan, aiming for Sustainable, Managed and Reasonable Treatment. Like Manulife’s DrugWatch, SMART will bring more rigourous review to selected new drugs and indications and likely delay product entry into its formularies.  Great-West Life indicates its reviews will not only rely on the Canadian Agency for Drugs and Technology in Health (CADTH).  As…

Changes, Updates and Reminders Related to CDR Guidelines   On Friday, June 9th, CADTH issued a CDR Update with a number of changes, updates, and reminders that are worth reviewing. The key highlights are: Two Process Changes Guidance for Subsequent Entry Non-Biological Complex Drugs Revised Documentation for Resubmissions Two Reminders (In-person CDR Meetings/Confidential Prices) Communication with Consultants Further detail, which has been drawn from the CDR Update, can be found…

Consultations Commence for Major Changes to Canadian Pharmaceutical Policy   On May 16, 2017, the Federal Minister of Health, the Hon. Jane Philpott presented several major announcements, which are likely to have significant impacts on both national and provincial/territorial pharmaceutical policy.  The announcements covered an array of developments including: changes to the regulations that govern how the Patented Medicine Prices Review Board (PMPRB) operates; enhancing the capacity of the pan-Canadian…